BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

7:19 PM
 | 
Jul 25, 2007
 |  BC Extra  |  Company News

Kuvan gets Priority Review

FDA accepted for filing and granted Priority Review to an NDA from BioMarin (BMRN; SWX:BMRN) for Kuvan sapropterin (formerly Phenoptin) to treat...

Read the full 97 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >